Co-Authors
This is a "connection" page, showing publications co-authored by JIUN-KAE JACK LEE and SUYU LIU.
Connection Strength
0.722
-
Bayesian adaptive randomization designs for targeted agent development. Clin Trials. 2010 Oct; 7(5):584-96.
Score: 0.373
-
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials. 2008; 5(3):181-93.
Score: 0.078
-
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
Score: 0.029
-
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
Score: 0.028
-
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
Score: 0.027
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.026
-
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
Score: 0.026
-
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
Score: 0.025
-
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
Score: 0.025
-
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep 01; 15(17):5359-68.
Score: 0.022
-
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009 Aug; 16(8):2181-7.
Score: 0.022
-
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol. 2009 Feb; 32(1):15-9.
Score: 0.021
-
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72.
Score: 0.019